PRODUCT

Licensed to Cure for BioPharma

Dassault Systèmes has launched a new 'industry solution experience' for pharmaceutical and biotech companies – 'Licensed to Cure for BioPharma'.

Based on Dassault Systèmes’ 3DEexperience platform, the product is said to transform the way biotech and pharmaceutical companies manage product and process complexity by smoothing drug variation, enabling easier and faster expansion into new markets, while managing increasing regulatory requirements.

In an environment of expiring patents, more stringent regulations and increased development costs, companies are increasingly turning to drug variations to drive growth. With one active pharmaceutical ingredient yielding as many as 1,000 finished products, a biopharmaceutical company must have a business platform that not only manages product knowledge complexity, but also simultaneously drives collaboration, innovation, and compliancy.

Dassault says Licensed to Cure for BioPharma boosts compliance strategies and creates a structured approach to manage product and process complexity, resulting in faster delivery of product variations to new markets.

Feature

Sophia Ktori investigates the use of informatics software to increase data integrity in the laboratory

Feature

Tim Gillett reports from PRACEDays 2016, held in May in the city of Prague

Feature

Robert Roe investigates the motivation behind the architectural changes to Europes fastest supercomputer, Piz Daint, housed at the Swiss National Computing Centre

Feature

Robert Roe discusses the merits of the latest storage technologies, including a push by storage providers to develop end-to-end platforms featuring intelligent data management systems

Feature

As AMD launches its latest FirePro GPU, Robert Roe investigates a new suite of open-source tools, released by the company that convert code from CUDA into C++